Diagnosis Protocol

Monitor for new-onset seizures, which occur in 2.6%–6.1% of patients (Class III) and may be caused by CNS opportunistic infections in up to 11% of cases.

Screen for peripheral neuropathy symptoms, which occur in 6.7%–52.5% of untreated HIV patients and develop in 17%–55% of patients after starting ARVs.

Screen for new-onset seizures, which occur in 2.6%–6.1% of patients (Class III) and are associated with a reported seizure incidence as high as 11% overall.

Perform a neurologic exam focusing on abnormal vibratory sensation in the feet or reduced ankle reflexes; 57% of patients exhibit at least one sign (Class II).

Screen for paresthesias or pain, as 61% of patients with clinical signs are symptomatic (Class II).

Monitor for the development of neuropathy symptoms, which occur in 17%–55% of patients previously asymptomatic at ARV initiation.

Screen for new-onset seizures, which occur in 2.6%–6.1% of patients (Class III) and are associated with a reported seizure incidence as high as 11% overall.

Perform a neurologic exam focusing on abnormal vibratory sensation in the feet or reduced ankle reflexes; 57% of patients exhibit at least one sign (Class II).

Screen for paresthesias or pain, as 61% of patients with clinical signs are symptomatic (Class II).

Monitor for the development of neuropathy symptoms, which occur in 17%–55% of patients previously asymptomatic at ARV initiation.